You are viewing: Canada AI in Biotechnology Market analysis
Part of: AI in Biotechnology Market (Global)

The Canada AI in Biotechnology Market was valued at $212.4 Million in 2030 and projected to reach to $436.6 Million by 2035, representing a compound annual growth rate of 15.8%. Canada's AI in biotechnology market is positioned for sustained growth through 2035, supported by the country's robust research infrastructure, favorable regulatory environment, and increasing collaboration between academic institutions and industry players.

Canada AI in Biotechnology Market (2030-2035) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Canada AI in Biotechnology Market Trends and Insights

  • This expansion reflects Canada's strong position in life sciences innovation and increasing adoption of artificial intelligence across drug discovery, genomics, and personalized medicine applications.
  • Canada's investment in AI-driven biotech solutions is accelerating as domestic companies and research institutions leverage machine learning to streamline clinical workflows and reduce time-to-market for therapeutics. The Canadian market benefits from a mature healthcare infrastructure, government support for biotech innovation, and a skilled workforce in computational biology.
  • Canada's pharmaceutical and biotech sectors are increasingly integrating AI tools for predictive analytics, protein folding, and patient stratification.
  • Between 2030 and 2035, Canada is expected to see heightened competition among both established players and emerging startups, driving technological advancement and market consolidation. Canada's regulatory environment and proximity to North American markets position the country as a key hub for AI biotechnology development.
  • The forecasted growth trajectory underscores Canada's commitment to becoming a leader in precision medicine and computational drug development within the broader North American ecosystem..

Key Market Statistics

  • CAGR (2030-2035) 15.8% CAGR
  • Market Size, 2030 ~USD 212.4 Million
  • Forecast, 2035 ~USD 436.6 Million
  • Country Canada

Canada AI in Biotechnology Market Overview

Market Valuation Growth :

Canada's AI in biotechnology market is valued at $212.4 million in 2030 and is projected to reach $436.6 million by 2035, representing a compound annual growth rate of 15.8% over the forecast period.

Life Sciences Innovation Hub :

Canada has established itself as a leading center for life sciences innovation, with strong government support, world-class research institutions, and a growing ecosystem of AI-driven biotech startups and established pharmaceutical companies.

Key Application Areas :

The Canadian market is experiencing significant adoption of AI across drug discovery, genomics analysis, and personalized medicine applications, driven by healthcare providers' need for faster, more accurate diagnostic and therapeutic solutions.

Investment and Funding Landscape :

Canada's commitment to AI-driven biotech solutions is reflected in substantial venture capital investments, government grants, and public-private partnerships that are accelerating the commercialization of innovative AI biotechnology platforms.

Canada AI in Biotechnology Market Dynamics

  • The market's 15.8% CAGR reflects growing adoption of AI technologies in drug development pipelines and precision medicine initiatives across Canadian healthcare systems.
  • Government initiatives promoting AI innovation and life sciences investment are expected to further accelerate market expansion, attracting both domestic and international biotech companies to establish operations in Canada..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Healthcare It

    Top Technologies
    • Computed Tomography (CT)
    • Machine Learning
    • Magnetic Resonance Imaging (MRI)
    • Natural Language Processing (NLP)
    • Predictive Analytics
    Top Companies
    • CERNER CORPORATION
    • PHILIPS HEALTHCARE
    • Oracle Corporation
    • GE HealthCare Technologies Inc.
    • Siemens healthineers

      Key Takeaways

      • Canada's AI in biotechnology market is valued at $212.4 million in 2030 and is forecast to double to $436.6 million by 2035, representing a 15.8% CAGR.
      • Canada's strong life sciences ecosystem, government funding, and skilled computational workforce are driving accelerated adoption of AI in drug discovery and genomics.
      • Canadian biotech companies are leveraging AI for predictive analytics, protein structure prediction, and patient stratification to improve clinical outcomes and reduce development timelines.
      • Canada's strategic location in North America, combined with favorable regulatory policies, positions the country as an emerging leader in AI-driven precision medicine and personalized therapeutics.

      AI in Biotechnology Market Report Scope

      Report Metric Details
      Base Year 2030
      Fastest Growing Segment DRUG DISCOVERY (Type)
      Forecast Period 2030–2035
      Growth Rate CAGR of 18.5% from 2030 to 2035
      Largest Segment CLOUD-BASED SOLUTIONS (Deployment Mode)
      Market Size Base Year (Billions) ~USD 9.72 (2030)
      Revenue Forecast (Billions) ~USD 22.72 (2035)
      Segments Covered Offering, Function, Type, Deployment Mode, End User

      Canada AI in Biotechnology Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Offering

      • End-To-End Solutions
      • Niche Solutions
      • Services
      • Technologies
      • Technology

      By Function

      • Corporate
      • Launch & Commercial
      • Manufacturing & Supply Chain
      • Post-Marketing Surveillance & Patient Support
      • Regulatory Compliance
      • Research & Development

      By Type

      • Adverse Event Reporting
      • Biomarker Discovery
      • Clinical Data Assessment
      • Clinical Development
      • Compliance Monitoring
      • Consulting Services
      • Demand Forecasting
      • Drug Discovery
      • Hybrid Cloud
      • Implementation Services & Ongoing It Support
      • Inventory Management
      • Launch Coordination
      • Logistics Optimization
      • Marketing Operations
      • Medication Adherence
      • Molecular Design & Optimization
      • Monitoring & Drug Adherence
      • Multi Cloud
      • Other Corporate Functions
      • Other Manufacturing & Supply Chain Functions
      • Patient Engagement
      • Patient Monitoring
      • Patient Support Programs
      • Post-Sales & Maintenance Services
      • Predictive Maintenance
      • Predictive Pricing
      • Predictive Toxicity & Risk Monitoring
      • Private Cloud
      • Public Cloud
      • Real-World Evidence (Rwe) Analysis
      • Real-World Evidence(Rwe) Analysis
      • Recruitment
      • Risk Management
      • Sales Force Optimization
      • Site Selection
      • Structure-Activity Relationship (Sar) Modeling
      • Supply Chain Planning
      • Training & Education Services
      • Trial Design

      By Deployment Mode

      • Cloud-Based Solutions
      • On-Premises Solutions

      By End User

      • Biotechnology Companies
      • Clinical Research Organizations
      • Contract Research Organizations
      • Healthcare Providers
      • Pharmaceutical Companies
      • Research Institutes & Labs

      Target Audience

      • Biotech & Pharmaceutical Companies : Canadian and international biotech firms need market sizing and growth projections to evaluate expansion opportunities, R&D investment allocation, and competitive positioning within Canada's AI-driven drug discovery landscape.
      • Venture Capital & Private Equity Investors : Investment firms require detailed market forecasts and segment analysis to identify high-potential AI biotech startups in Canada, assess portfolio company valuations, and optimize capital deployment strategies.
      • Healthcare Providers & Hospital Networks : Canadian healthcare systems need market intelligence on AI biotechnology solutions to inform procurement decisions, evaluate personalized medicine adoption, and plan digital transformation initiatives.
      • Government & Policy Makers : Federal and provincial government agencies require market data to design effective innovation policies, allocate research funding, and develop strategies to strengthen Canada's competitive position in AI biotechnology.
      • Research Institutions & Academic Centers : Universities and research organizations need market insights to guide commercialization strategies, identify collaboration opportunities with industry, and align research programs with market demand in AI biotechnology.

      Key Companies in the Canada AI in Biotechnology Market

      CompanyHQOwnershipStrongest segments
      NVIDIA CORPORATIONUnited StatesPublic CompanyData Center AI Compute & Networking,Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro),
      ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Arrays and genotyping consumables,
      RECURSIONUnited StatesPublic CompanyPlatform collaboration and milestones,Internal pipeline R&D funding (capitalized/other income),Other services and data partnerships,
      SCHRöDINGER, INC.United StatesPublic CompanySoftware,Drug Discovery – Collaborations (e.g., Novartis and others),Drug Discovery – Internal Pipeline,
      BENEVOLENTAIUnited KingdomPrivate CompanyAI discovery platform and licenses,Collaborative R&D projects and services,Custom data/ontology and analytics solutions,
      QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Molecular diagnostics assays (TB, oncology, sexual and reproductive health, transplant, viral load),PCR and digital PCR instruments and consumables,
      TEMPUSUnited StatesPublic CompanyOncology NGS diagnostics (xT, xR, solid tumor and hematologic panels),Other diagnostics (PCR profiling, pathology, inherited conditions, pharmacogenomics nP),Data licensing and software (Insights, Lens, Hub, Next, Algos, Organoids, Trials),
      SOPHIA GENETICSSwitzerlandPublic CompanySOPHiA DDM platform subscriptions and usage-based analytics,Implementation, support, and workflow services,Biopharma collaborations and data-driven research solutions,
      PREDICTIVE ONCOLOGYUnited StatesPublic CompanyCompute Services and Treasury Management,Drug Discovery Services,
      XTALPI INC.ChinaPublic CompanyAI-driven drug discovery solutions (hit discovery, optimization, biology, PepiX),Computational software platforms (XFEP, XMolGen, PatSight, XtalGazer),Automation hardware and integrated workstations (XmartChem, ChemPlus),

      NVIDIA CORPORATION

      NVIDIA Corporation is a publicly traded technology company founded in 1993 and headquartered in the United States. With 42,000 employees, the company designs and manufactures graphics processing units and system-on-chip units. NVIDIA serves markets including gaming, professional visualization, data centers, and artificial intelligence.

      ILLUMINA, INC.

      Illumina, Inc. is a publicly traded genomics company founded in 1998 and based in the United States. The company employs 8,625 people and specializes in DNA sequencing and array-based technologies. Illumina's platforms are used for applications in research, clinical diagnostics, and precision medicine.

      RECURSION

      Recursion is a publicly traded biotechnology company founded in 2013 and headquartered in the United States. With 600 employees, the company uses machine learning and high-throughput biology to discover and develop therapeutics. Recursion focuses on identifying novel drug candidates through computational and experimental approaches.

      SCHRöDINGER, INC.

      Schrödinger, Inc. is a publicly traded computational chemistry and drug discovery company founded in 1990 and based in the United States. The company employs 850 people and develops software platforms for molecular simulation and drug design. Schrödinger's tools are used by pharmaceutical and biotechnology companies to accelerate drug development.

      BENEVOLENTAI

      BenevolentAI is a privately held artificial intelligence company founded in 2013 and headquartered in the United Kingdom. With 173 employees, the company applies machine learning and AI to drug discovery and development. BenevolentAI focuses on identifying new therapeutic targets and repurposing existing drugs for various diseases.

      QIAGEN

      QIAGEN is a publicly traded life sciences company founded in 1984 and headquartered in the Netherlands. With 5,500 employees, the company develops and manufactures sample preparation and molecular testing technologies. QIAGEN serves customers in molecular diagnostics, applied testing, and academic research.

      TEMPUS

      Tempus is a publicly traded artificial intelligence and precision medicine company founded in 2015 and based in the United States. With 3,800 employees, the company leverages machine learning and data analytics to improve cancer treatment and outcomes. Tempus analyzes clinical and molecular data to provide actionable insights for oncology care.

      SOPHIA GENETICS

      Sophia Genetics is a publicly traded digital health company founded in 2011 and headquartered in Switzerland. With 415 employees, the company develops AI-powered platforms for genomic data interpretation and clinical decision support. Sophia Genetics serves hospitals, diagnostic laboratories, and research institutions globally.

      PREDICTIVE ONCOLOGY

      Predictive Oncology is a publicly traded cancer diagnostics and treatment company founded in 2002 and based in the United States. With 14 employees, the company develops personalized medicine solutions for oncology patients. Predictive Oncology focuses on tumor profiling and treatment prediction technologies.

      XTALPI INC.

      XtalPi Inc. is a publicly traded artificial intelligence and drug discovery company founded in 2015 and headquartered in China. The company uses machine learning and computational chemistry to accelerate drug discovery and development. XtalPi focuses on molecular simulation and structure-based drug design.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Obtain precise valuation data for Canada's AI biotechnology market with verified CAGR of 15.8%, enabling accurate financial forecasting and investment decision-making for the 2030-2035 period.
      • Competitive Landscape Intelligence : Understand Canada's position relative to global markets (18.5% global CAGR) and identify competitive advantages, emerging players, and market consolidation opportunities specific to the Canadian biotech ecosystem.
      • Sector-Specific Application Insights : Access detailed analysis of AI adoption across Canadian drug discovery, genomics, and personalized medicine segments to identify high-growth opportunities and technology integration strategies.
      • Regulatory & Investment Framework : Gain comprehensive understanding of Canada's regulatory environment, government funding mechanisms, and public-private partnership models that are driving market growth and innovation.
      • Strategic Market Entry Planning : Leverage Canada-specific market data to develop targeted go-to-market strategies, identify key stakeholders, and assess partnership opportunities with Canadian research institutions and healthcare providers.

      Frequently asked questions

      What is the current size of Canada's AI in biotechnology market?

      Canada's AI in biotechnology market is valued at $212.4 million in 2030 and is projected to grow to $436.6 million by 2035, reflecting strong demand for AI-driven drug discovery and personalized medicine solutions.

      What is the expected growth rate for Canada's AI biotechnology market?

      Canada's AI in biotechnology market is expected to grow at a compound annual growth rate (CAGR) of 15.8% from 2030 to 2035, outpacing many other sectors within Canada's healthcare industry.

      Which applications are driving growth in Canada's AI biotechnology market?

      Key applications driving Canada's market growth include AI-powered drug discovery, genomic analysis, protein structure prediction, clinical trial optimization, and patient stratification for personalized medicine.

      What factors support Canada's AI biotechnology market expansion?

      Canada's growth is supported by government biotech funding initiatives, a skilled computational biology workforce, established pharmaceutical infrastructure, and strong academic research institutions focused on AI and life sciences.

      How does Canada's market compare to the broader North American region?

      Canada represents a significant portion of North America's AI biotechnology market, with its 15.8% CAGR reflecting strong regional demand and positioning Canada as a key innovation hub alongside the United States.

      RESEARCH METHODOLOGY

      This market research study primarily relied on secondary sources, directories, and databases to collect information for this technical, market-oriented, and financial analysis of the AI in biotechnology market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives from major market players, and industry consultants, among others, to gather and verify critical qualitative and quantitative data and assess market prospects. The size of the AI in biotechnology market was estimated using multiple secondary research methods and confirmed with inputs from primary research to determine the final market size.

      Secondary Research

      The secondary research process involved extensively using secondary sources, including directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the World Health Organization (WHO), the Organization for Economic Co-operation and Development (OECD), Healthcare Information and Management Systems Society (HIMSS), Centers for Disease Control and Prevention (CDC), ClinicalTrials.gov, expert interviews, and MarketsandMarkets analysis.

      Secondary research was conducted to gather information for the detailed, technical, market-focused, and commercial analysis of the AI in biotechnology market. It was also used to collect key information about major players, market classification, and segmentation based on industry trends, down to the most detailed level, along with significant developments related to market and technology perspectives. Additionally, a database of leading industry players was compiled using secondary research.

      Primary Research

      During the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. Primary sources mainly include industry experts from core and related industries, preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations involved in all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, such as key industry participants, subject-matter experts (SMEs), C-level executives of leading market players, and industry consultants, among other specialists, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

      Primary research was conducted to identify segmentation types, industry trends, key players, and key market dynamics such as drivers, restraints, opportunities, challenges, and strategies adopted by key players.

      After completing the market engineering process- which includes calculations for market statistics, market breakdown, size estimations, forecasting, and data triangulation- extensive primary research was carried out. This research aimed to gather information and verify the key numbers obtained during the market analysis. Additionally, primary research was used to identify different types of market segmentation, analyze industry trends, evaluate the competitive landscape of AI solutions for biotechnology offered by various players, and understand key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies employed by key market players.

      In the complete market engineering process, the top-down and bottom-up approaches, along with several data triangulation methods, were extensively used to estimate and forecast the market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was conducted on the entire market engineering process to identify key information and insights throughout the report.

      Breakdown of Primary Interviews

      AI in Biotechnology Market

      Note 1: Others include sales, marketing, and product managers.

      Note 2: Tiers are defined based on a company’s total revenue, as of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The market size estimates and forecasts in this study are based on a combination of the bottom-up approach (revenue share analysis of leading players) and the top-down approach (evaluation of utilization, adoption, and penetration trends by offering, function, deployment mode, end user, and region).

      AI in Biotechnology Market

      Data Triangulation

      After determining the overall market size from the estimation process described above, the market for AI in biotechnology was divided into various segments and subsegments. To finalize the overall market analysis and obtain accurate statistics for all segments and subsegments, data triangulation and market breakdown techniques were used whenever applicable. The data was cross-verified by examining different factors and trends from both the demand and supply sides of the market for AI in biotechnology.

      Market Definition

      The AI in biotechnology market includes technologies that use artificial intelligence to advance drug discovery, genomics, and personalized medicine. This market is defined by the growing utilization of machine learning and data analytics to improve research and development efficiency.

      Stakeholders

      • Healthcare IT service providers
      • Pharmaceutical/Biopharmaceutical companies
      • Biotechnology firms
      • AI technology providers
      • Academic & research institutions
      • Academic medical centers/universities/hospitals
      • Regulatory agencies
      • Clinical research organizations (CROs)
      • Genomic testing labs
      • Government agencies
      • Startups in AI and biotech
      • Pharmaceutical supply chain partners
      • Consulting firms
      • Clinical trial management system providers
      • Bioinformatics companies
      • Advocacy groups
      • Investors & financial institutions

      Report Objectives

      • To define, describe, and forecast the AI in biotechnology market by offering, function, deployment mode, end user, and region
      • To provide detailed information regarding the major drivers, restraints, opportunities, and challenges influencing market growth
      • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall AI in biotechnology market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the AI in biotechnology market in five main regions (and their respective countries): North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
      • To provide key industry insights, such as value chain, regulatory, patent, and recession impact analysis
      • To profile the key players in the market and comprehensively analyze their core competencies
      • To track and analyze competitive developments, such as product launches & upgrades, collaborations, partnerships, acquisitions, investments, contracts, agreements, alliances, mergers, funding, and expansions of the leading players in the market
      • To benchmark players within the market using the company evaluation matrix, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering

      Get the Full AI in Biotechnology Market Report

      Full forecast, segment splits, and company analysis for all AI in Biotechnology Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status